Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.66 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 5/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | FPR1 | P21462 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28455839 | 0.98 | ESR2 (0.63) | ESR2PTPN5CNR1CNR2ADORA2A | |
| SCHEMBL31410710 | 0.87 | ESR2 (0.76) | ESR2PTPN5TRPA1CYP1A2GABRG2 | |
| SCHEMBL3520118 | 0.84 | ESR2 (0.49) | ESR2PTPN5CNR1CNR2ADORA2A | |
| Hydrochloric Acid SCHEMBL4082919 | 0.83 | ESR2 (0.47) | ESR2PTPN5CNR1CNR2ADORA2A | |
| SCHEMBL2016996 | 0.83 | ESR2 (0.70) | ESR2PTPN5CNR2TRPA1CYP1A2 | |
| SCHEMBL3954416 | 0.83 | CYP1A2 (0.48) | ESR2ADORA2AADORA1CYP1A2PTGS2 | |
| SCHEMBL23624362 | 0.82 | ESR2 (0.46) | ESR2CNR1CNR2ADORA2AADORA1 | |
| SCHEMBL29662886 | 0.82 | ESR2 (0.69) | ESR2PTPN5TRPA1CYP1A2LRRK2 | |
| SCHEMBL223 | 0.82 | ESR2 (0.69) | ESR2PTPN5TRPA1CYP1A2LRRK2 | |
| SCHEMBL27895577 | 0.82 | ESR2 (0.69) | ESR2PTPN5TRPA1CYP1A2GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109665990-B | Boscalid synthesis process | 安徽赛乐普制药有限公司 | 2020-08-28 | — | — | CN | claimed |
| CN-110494442-B | Peptide macrocycles and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230167097-A1 | HETEROCYCLIC COMPOUND HAVING CYANO-SUBSTITUTION | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167097-A1 | HETEROCYCLIC COMPOUND HAVING CYANO-SUBSTITUTION | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| CN-109665990-B | Boscalid synthesis process | 安徽赛乐普制药有限公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| EP-2308812-A2 | N-acylsulfonamide apoptosis promoters | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100240715-A1 | Apoptosis promoters | ABBOTT LABORATORIES | 2010-09-23 | — | — | US | disclosed |
| US-7767684-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | ESR2 876/4885PTPN5 3930/4885CNR1 4654/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | ESR2 876/4885PTPN5 3930/4885CNR1 4654/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | ESR2 876/4885PTPN5 3930/4885CNR1 4654/4885 |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | ESR2 876/4885PTPN5 3930/4885CNR1 4654/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | ESR2 2390/4885PTPN5 3815/4885CNR1 4444/4885 |
| US-20100240715-A1 | Apoptosis promoters | BAX, BCL2, API5 | ESR2 876/4885PTPN5 3930/4885CNR1 4654/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | ESR2 876/4885PTPN5 3930/4885CNR1 4654/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | ESR2 2782/4885PTPN5 1465/4885CNR1 1945/4885 |
| US-20230167097-A1 | HETEROCYCLIC COMPOUND HAVING CYANO-SUBSTITUTION | KCNH1, MCM4, MCM2 | ESR2 1501/4885PTPN5 4253/4885CNR1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.